Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 964.8 INR -0.72%
Market Cap: 970.8B INR
Have any thoughts about
Zydus Lifesciences Ltd?
Write Note

Zydus Lifesciences Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zydus Lifesciences Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Total Equity
â‚ą198.3B
CAGR 3-Years
7%
CAGR 5-Years
14%
CAGR 10-Years
18%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
â‚ą307.5B
CAGR 3-Years
18%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
â‚ą283.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
â‚ą691.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
â‚ą75B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Equity
â‚ą93.6B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Market Cap
970.8B INR
Industry
Pharmaceuticals

Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets. The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.

ZYDUSLIFE Intrinsic Value
675.81 INR
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Total Equity?
Total Equity
198.3B INR

Based on the financial report for Sep 30, 2024, Zydus Lifesciences Ltd's Total Equity amounts to 198.3B INR.

What is Zydus Lifesciences Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
18%

Over the last year, the Total Equity growth was 6%. The average annual Total Equity growth rates for Zydus Lifesciences Ltd have been 7% over the past three years , 14% over the past five years , and 18% over the past ten years .

Back to Top